Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.

被引：0
|
作者：
Wang, Wei-Hu
Xing, Baocai
Wang, Hongzhi
Zhu, Xianggao
Wang, Kun
Zheng, Xuan
Dong, Dezuo
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Radiat Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Hepatopancreatobiliary Surg Unit 1, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16157
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
    Xia, Yongxiang
    Wang, Ping
    Pu, Liyong
    Qian, Xiaofeng
    Cheng, Feng
    Wang, Ke
    Zhang, Chuanyong
    Li, Donghua
    Li, Xiangcheng
    Zhang, Feng
    Zhao, Jie
    Li, Si
    Xi, Wenjing
    Wang, Xuehao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
    Ju, Shuguang
    Zhou, Chen
    Hu, Junwen
    Wang, Yingliang
    Wang, Chaoyang
    Liu, Jiacheng
    Yang, Chongtu
    Huang, Songjiang
    Li, Tongqiang
    Chen, Yang
    Bai, Yaowei
    Yao, Wei
    Xiong, Bin
    BMC CANCER, 2022, 22 (01)
  • [3] Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
    Shuguang Ju
    Chen Zhou
    Junwen Hu
    Yingliang Wang
    Chaoyang Wang
    Jiacheng Liu
    Chongtu Yang
    Songjiang Huang
    Tongqiang Li
    Yang Chen
    Yaowei Bai
    Wei Yao
    Bin Xiong
    BMC Cancer, 22
  • [4] The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Chen, Bin
    Lin, Run
    Huang, Yonghui
    Dai, Haitao
    Tang, Keyu
    Zhang, Guiyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy of camrelizumab and apatinib combination therapy versus apatinib only in treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Swed, Sarya
    Motawea, Karam R.
    AbdelQadir, Yossef Hassan
    Gamal, Mohamed
    El-Sakka, Amro A.
    Kandil, Omneya A.
    Abdelazeem, Basel
    Abdelaziz, Muhammad
    Wahsh, Engy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16147 - E16147
  • [6] Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center
    Zhang, Jin-Xing
    Chen, Yu-Xing
    Zhou, Chun-Gao
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Zu, Qing-Quan
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 2022
  • [7] Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study
    Jing, Chao
    Bai, Zhigang
    Tong, Kuinan
    Yang, Xiaobao
    Liu, Kun
    Wu, Hongwei
    Zhu, Jiegao
    Guo, Wei
    Zhang, Zhongtao
    Deng, Wei
    ONCOLOGIST, 2024, 29 (11): : e1565 - e1574
  • [8] Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
    Yuan, Guosheng
    Cheng, Xiao
    Li, Qi
    Zang, Mengya
    Huang, Wei
    Fan, Wenzhe
    Wu, Tao
    Ruan, Jian
    Dai, Wencong
    Yu, Wenxuan
    Chen, Mian
    Guo, Yabing
    Hu, Xiaoyun
    Chen, Jinzhang
    ONCOTARGETS AND THERAPY, 2020, 13 : 12683 - 12693
  • [9] Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
    Zhang, Xuexian
    Wang, Ruidong
    Ding, Yuhan
    Li, Qingwei
    Feng, Xiong
    Hong, Ren
    Jun, Zhang
    Wei, Li
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [10] Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
    Zhang, Jin-Xing
    Chen, Pei
    Liu, Sheng
    Zu, Qing-Quan
    Shi, Hai-Bin
    Zhou, Chun-Gao
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 265 - 272
12345